EF 7412
Latest Information Update: 17 Oct 2007
Price :
$50 *
At a glance
- Originator CEPA Schwarz Pharma
- Developer CEPA Schwarz Pharma; Nonindustrial source
- Class Antidepressants; Piperazines; Small molecules; Sulfonamides
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 20 Jun 2001 No-Development-Reported for Depression in Spain (Unknown route)
- 17 Mar 1998 Preclinical development for Depression in Spain (Unknown route)